Lineage Cell Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2025-03-31 was $3.79M.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $784.00K.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-06-30 was $5.84M.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2021-09-30 was $2.67M.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $6.63M.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2021 was $29.82M, a 451.76% increase from fiscal 2020.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2020 was $5.40M, a 5146.60% increase from fiscal 2019.
- Lineage Cell Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2019 was $103.00K.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2025-03-31 | $3.79M 10-Q · filed 2026-05-12 | |
| 2023-12-31 | $6.63M 10-K · filed 2024-03-07 | |
| 2023-09-30 | $784.00K 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $5.84M 10-Q · filed 2023-11-09 | |
| 2021-12-31 | $29.82M 10-K · filed 2023-03-09 | |
| 2021-09-30 | $2.67M 10-Q · filed 2022-11-10 | |
| 2021-06-30 | $7.87M 10-Q · filed 2022-11-10 | |
| 2021-03-31 | $19.01M 10-Q · filed 2022-11-10 | |
| 2020-12-31 | $5.40M 10-K · filed 2022-03-10 | |
| 2019-12-31 | $103.00K 10-K · filed 2021-03-11 | |
| 2017-12-31 | $45.07M 10-K · filed 2019-03-14 | |
| 2016-12-31 | $18.61M 10-K · filed 2018-03-15 | |
| 2015-12-31 | $33.90M 10-K · filed 2018-03-15 | |
| 2014-12-31 | $43.83M 10-K · filed 2017-03-16 | |
| 2013-12-31 | $10.73M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $22.30M 10-K · filed 2016-03-15 |
| 2013-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | |
| 2012-12-31 | $1.00M 10-K · filed 2015-03-11 | |
| 2009-12-31 | $8.00M 10-K · filed 2012-03-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |